首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1413篇
  免费   125篇
  国内免费   37篇
耳鼻咽喉   36篇
儿科学   68篇
妇产科学   32篇
基础医学   198篇
口腔科学   60篇
临床医学   125篇
内科学   199篇
皮肤病学   42篇
神经病学   109篇
特种医学   174篇
外科学   160篇
综合类   96篇
预防医学   44篇
眼科学   52篇
药学   70篇
  2篇
中国医学   10篇
肿瘤学   98篇
  2023年   22篇
  2022年   64篇
  2021年   68篇
  2020年   57篇
  2019年   42篇
  2018年   68篇
  2017年   48篇
  2016年   53篇
  2015年   54篇
  2014年   98篇
  2013年   112篇
  2012年   52篇
  2011年   62篇
  2010年   45篇
  2009年   62篇
  2008年   53篇
  2007年   62篇
  2006年   51篇
  2005年   30篇
  2004年   42篇
  2003年   34篇
  2002年   33篇
  2001年   15篇
  2000年   25篇
  1999年   22篇
  1998年   22篇
  1997年   14篇
  1996年   14篇
  1995年   20篇
  1994年   16篇
  1993年   15篇
  1992年   17篇
  1991年   10篇
  1990年   14篇
  1989年   17篇
  1988年   12篇
  1987年   10篇
  1986年   7篇
  1985年   19篇
  1984年   16篇
  1983年   4篇
  1982年   14篇
  1981年   11篇
  1980年   9篇
  1979年   6篇
  1978年   10篇
  1977年   6篇
  1976年   5篇
  1975年   2篇
  1974年   6篇
排序方式: 共有1575条查询结果,搜索用时 15 毫秒
81.
PURPOSE: To correlate prenatal sonographic diagnosis of cystic lung malformations with fetopathologic findings after termination of pregnancy. METHODS: We retrospectively analyzed the data of 16 terminated cases in which a cystic lung lesion was diagnosed pre- or postnatally. RESULTS: On average, prenatal diagnosis was established on the 21(st) gestational week (range, 19-26 weeks). The cause of termination was severe polyhydramnios in 4 cases, nonimmune fetal hydrops in 4 cases, other congenital malformation in 5 cases (renal malformation, 2 cases; congenital diaphragmatic hernia, 3 cases), and obstetrical conditions (intrauterine death, placental abruption, spontaneous abortion) in 3 cases. In 11 cases, congenital cystic adenomatoid malformation (CCAM) was the presumptive prenatal diagnosis. Autopsy confirmed the prenatal diagnosis in 6 of them, while in the other 5 cases, an enteric cyst, a laryngeal atresia, an unidentified tumor, a pulmonary hypoplasia, and an extralobar pulmonary sequestration were found on histologic examination. On the other hand, the autopsy revealed CCAM in those 5 cases in which other malformations were suggested prenatally. CONCLUSION: The prenatal sonographic diagnosis of CCAM is difficult. Our cases emphasize the important role of fetopathology even today in the verification of prenatal diagnosis based on sonographic examinations.  相似文献   
82.
目的:原发性滑膜骨软骨瘤病又称滑膜软骨化生,非常罕见,是发生在关节囊、滑囊和腱鞘滑膜的慢性关节病,非常罕见,病因不明,可能与外伤有关。结果好发于30~50岁男性,以膝关节发生率最高,占68.99%,其次为髋关节、肩关节、肘关节、踝关节等,常单侧关节发病,双侧少见。结论临床表现为受累的关节肿胀,疼痛明显,关节穿刺可抽出积液。以手术治疗为主,需摘除关节腔内游离体,同时需广泛切除病变的滑膜,该病复发率较高。  相似文献   
83.
目的研究活检术前应用皮质醇是否会影响原发性中枢神经系统淋巴瘤的病理诊断。方法回顾分析2005年2月至2011年2月期间73例经立体定向活检诊断为原发性中枢神经系统淋巴瘤患者的资料。结果 73例淋巴瘤患者中,39例(53.4%)在活检术前应用皮质醇;10例(73;13.7%)未得出阳性结果,再次行立体定向活检或开颅被证实为原发性中枢神经系统淋巴瘤,其中5例(39例)术前应用过皮质醇(12.8%),5例(34例)未使用皮质醇(14.7%)(P=1.0)。结论活检术前应用皮质醇对大部分原发性中枢神经系统淋巴瘤患者而言不影响其病理诊断。  相似文献   
84.

Background

To diagnose sputum smear-negative pulmonary tuberculosis (PTB) is difficult and the ability of high-resolution computed tomography (HRCT) for diagnosing PTB has remained unclear in the sputum smear-negative setting. We retrospectively investigated whether or not this imaging modality can predict risk for sputum smear-negative PTB.

Methods

We used HRCT to examine the findings of 116 patients with suspected PTB despite negative sputum smears for acid-fast bacilli (AFB). We investigated their clinical features and HRCT-findings to predict the risk for PTB by multivariate analysis and a combination of HRCT findings by stepwise regression analysis. We then designed provisional HRCT diagnostic criteria based on these results to rank the risk of PTB and blinded observers assessed the validity and reliability of these criteria.

Results

A positive tuberculin skin test alone among clinical laboratory findings was significantly associated with an increase of risk of PTB. Multivariate regression analysis showed that large nodules, tree-in-bud appearance, lobular consolidation and the main lesion being located in S1, S2, and S6 were significantly associated with an increased risk of PTB. Stepwise regression analysis showed that coexistence of the above 4 factors was most significantly associated with an increase in the risk for PTB. Ranking of the results using our HRCT diagnostic criteria by blinded observers revealed good utility and agreement for predicting PTB risk.

Conclusions

Even in the sputum smear-negative setting, HRCT can predict the risk of PTB with good reproducibility and can select patients having a high probability of PTB.  相似文献   
85.
目的探讨肝硬化失代偿期并发意外肝癌患者的肝移植效果及其临床特点。方法11例肝硬化失代偿期患者接受原位肝移植,在术后的病肝病理检查中意外发现癌灶(称之为"意外肝癌"),其原发病,8例为乙型肝炎后肝硬化,丙型肝炎后肝硬化、酒精性肝硬化和原发性硬化性胆管炎各1例。11例术后采用他克莫司、霉酚酸酯及甲泼尼龙预防排斥反应,3个月后撤除霉酚酸酯,6个月后撤除甲泼尼龙。病肝沿水平面作间隔1 cm连续平行切片,对于直径大于1 cm或有灰白色结节者,完整取材。结果11例中,术前仅4例(36.4%,4/11)的甲胎蛋白(AFP)水平超过正常值。除1例肿瘤为多发外,其余均为单发,肿瘤直径最大为2.0 cm,平均直径为1.18 cm;肿瘤TNM分期,Ⅰ期占72.7%,Ⅲ期占27.3%;存在微血管侵犯2例,包膜完整、无血管及淋巴侵犯2例;病理诊断为胆管细胞癌1例,肝细胞癌10例。术后随访12~50个月,1例因肿瘤复发于术后10个月死亡。结论意外肝癌的病理学特点为肿瘤分期早,多为单发,组织分化程度高,肝移植后的1年存活率与良性肝病患者肝移植类似,肿瘤复发率低。  相似文献   
86.
87.
Poly-ɛ-caprolactone (PCL) is now widely studied in relation to the engineering of bone, cartilage, tendons, and other tissues. Standard histological protocols can destroy the carefully created trabecular and honeycomb-like architecture of PCL scaffolds, and could lead to scaffold fibers swelling, resulting in the displacement or compression of tissues inside the scaffold. The aim of this study was to modify a standard histopathological protocol for PCL scaffold preparation and evaluate it on porous cylindrical PCL scaffolds in a rat model. In 16 inbred Wag rats, 2 PCL scaffolds were implanted subcutaneously to both inguinal areas. Two months after implantation, harvested scaffolds were first subjected to μCT imaging, and then to histopathological analysis with standard (left inguinal area) and modified histopathological protocols (right inguinal area). To standardize the results, soft tissue percentages (STPs) were calculated on scaffold cross-sections obtained from both histopathological protocols and compared with corresponding µCT cross-sections. The modified protocol enabled the assessment of almost 10× more soft tissues on the scaffold cross-section than the standard procedure. Moreover, STP was only 1.5% lower than in the corresponding µCT cross-sections assessed before the histopathological procedure. The presented modification of the histopathological protocol is cheap, reproducible, and allows for a comprehensive evaluation of PCL scaffolds while maintaining their trabecular, honeycomb-like structure on cross-sections.  相似文献   
88.
Nanoparticles for colon-drug delivery were designed and evaluated to solve many discrepancy issues such as high adverse effects of released drugs, insufficient drug amount at diseased areas, and unintentionally premature drug release to noninflamed GIT regions. Herein, the goal of this work was to convert trimebutine maleate (TMB) into nanostructured lipid carriers (NLC) in order to improve its protective effects in ulcerative colitis. NLC of TMB was prepared by the hot homogenization followed by ultra-sonication method. A full 42-factorial design was used to estimate the produced TMB-NLC. The study design included the exploration of the impact of two independent variables namely lipid mix amount and ratio (glyceryl mono stearate and capryol 90), surfactant concentration (0.5, 1, 1.5, and 2%), on the particle size, polydispersity index, and the entrapment efficiency (EE%). The protective activity of F9 was examined through macroscopical scores, histopathological changes, immunohistochemical localization of tumor necrosis factor-α (TNF-α) and examination of oxidative stress such as reduced glutathione (GSH), superoxide dismutase (SOD), and malondialdehyde (MDA) against acetic acid-induced colitis in rats. Consistent with our expectations, the orally administered optimized formula (F9) alleviated the severity of colitis in acetic acid-induced rat model of colitis likely owing to the controlled release compared to free TMB. We aimed to develop TMB-loaded NLC for the treatment of acute colitis with the goal of providing a superior drug safety profile over long-term remission and maintenance therapy.  相似文献   
89.
90.
《Pharmaceutical biology》2013,51(4):408-415
Objective: Punarnavashtak kwath (PNK) is a classical Ayurvedic formulation, mentioned in Ayurvedic literature Bhaishajya Ratnavali, for hepatic disorders and asthma. This study investigated the hepatoprotective activity of PNK to validate the traditional use of this formulation.

Materials and methods: PNK was prepared in the laboratory according to the method given in Ayurvedic literature. Phytochemical screening was performed to determine the presence of phytoconstituents. Hepatoprotective activity was evaluated against CCl4-induced hepatotoxicity in rats and by its effect on the HepG2 cell line.

Results: Preliminary phytochemical screening revealed the presence of alkaloids, tannins, flavonoids, saponins, and a bitter principle in PNK. Administration of PNK produced significant hepatoprotective effect as demonstrated by decreased levels of serum liver marker enzymes such as aspartate transaminase, serum alanine transaminase, serum alkaline phosphatase, and serum bilirubin and an increase in protein level. Thiopentone-induced sleeping time was also decreased in the PNK-treated animals compared with the CCl4-treated group. It also showed antioxidant activity by increase in activity of glutathione, superoxide dismutase, and catalase and by a decrease in thiobarbituric acid reactive substance level compared with the CCl4-treated group. Results of a histopathological study also support the hepatoprotective activity of PNK. Investigation carried out on the HepG2 cell line depicted significant increase in viability of cells exposed to PNK as compared with CCl4-treated cells.

Discussion and Conclusion: It can be concluded that PNK protects hepatocytes from CCl4-induced liver damages due to its antioxidant effect on hepatocytes. An in vitro study on HepG2 cell lines also supports its protective effect.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号